Dissected subgroups predict the risk of recurrence of stage II colorectal cancer and select rational treatment

BACKGROUND: Stage II colorectal cancer(CRC) patients after surgery alone have a five-year survival rate of ~60-80%; the incremental benefit of adjuvant chemotherapy is <5%. Predicting risk of recurrence and selecting effective personalized adjuvant drugs for stage II CRC using formalin-fixed, par...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Fulong, Lu, Shixun, Zhou, Xin, Di, Xiaotang, Wu, Rujia, Chen, Gong, Tian, Sun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10076777/
https://www.ncbi.nlm.nih.gov/pubmed/37033948
http://dx.doi.org/10.3389/fimmu.2023.1103741

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10076777/
https://www.ncbi.nlm.nih.gov/pubmed/37033948
http://dx.doi.org/10.3389/fimmu.2023.1103741

Ejemplares similares